All In Biotech

Drug Trial Radar · NCT01192568

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients

Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

May 17, 2011

Primary completion

Aug 29, 2023

Study completion Oct 24, 2023

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks.

Conditions

  • Overactive Detrusor
  • Neurogenic Bladder

Interventions

  • OxybutyninDrug

    10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.

  • PlaceboDrug

    Topical gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Percent of Catheterizations Without a Leaking Accident at Week 6Time frame: Baseline (Week 0) up to Week 6

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University /ID# 236889

    Loma Linda, California

  • Child Hosp of Orange County,CA /ID# 237517

    Orange, California

  • Children's Hospital Colorado - Aurora /ID# 237620

    Aurora, Colorado

  • Augusta University Medical Center /ID# 238188

    Augusta, Georgia

  • University of Mississippi Medical Center /ID# 238065

    Jackson, Mississippi

  • Albany Medical College /ID# 236880

    Albany, New York

  • Duke University /ID# 237494

    Durham, North Carolina

  • Duplicate_Oregon Health & Science University /ID# 234354

    Portland, Oregon

  • Cook Children's Med. Center /ID# 237538

    Fort Worth, Texas

  • Child Hosp of the King's Dtr's /ID# 237799

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.